Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)
Latest Information Update: 03 Aug 2023
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ImmunoProst
- 24 Aug 2021 Planned number of patients changed from 29 to 38.
- 24 Aug 2021 Planned End Date changed from 1 Jan 2021 to 1 Mar 2022.
- 24 Aug 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2022.